Skip To Main Content
Katherine Chu on Muck Rack

Katherine Chu

As seen in: Nature

Get in touch with Katherine

Contact Katherine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Biomarkers of nivolumab benefit in resectable non-small cell lung cancer

|
By Tina Cascone, Mark Awad, Jonathan Spicer Verified, Jie He, Shun Lu, Fumihiro Tanaka, Robin Cornelissen, Lubos Petruzelka, Yang Gao Verified, Jean-Louis Pujol, Hiroyuki Ito, Tudor-Eliade Ciuleanu, Lin Wu, Sabine Bohnet, Yasutaka Watanabe, Janis Taube, Julie Stein Deutsch, Yu-Han Hung, Padma Sathyanarayana, Sumeena Bhatia, Katherine Chu, Steven Blum Verified, Stefano Lucherini, Akshay Yadav, Mariano Provencio, Cinthya Coronado Erdmann, Stephanie Meadows-Shropshire, Jaclyn Neely, Virginia Ip, Nathanial Eddy
| Nature Verified
Abstract Perioperative nivolumab significantly improved event-free survival (EFS) compared with placebo in patients with resectable non-small cell lung cancer (NSCLC) in the CheckMate 77T study (ClinicalTrials.gov NCT04025879)1. Here, after randomization, 98 out of 229 patients who received nivolumab and 92 out of 232 patients who received placebo had evaluable biomarkers (41% of randomized patients).
Open in Who Shared Issue with article?
See all 1 articles